Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PMHNP > Antidepressants (Week 3/4) > Flashcards

Antidepressants (Week 3/4) Flashcards

1
Q

Monoamine hypothesis of depression

A

Hypothesis involving deficiency of monoamine neurotransmitters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Neurotransmitter receptor hypothesis of antidepressant action

A

hypothesis involving monoamine neurotransmitters and their receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Mnemonic for depressive disorders

A

S: Sleep
I: Interest
G:Guilt
E: Energy
C: Concentration
A: Appetite
P:psychomotor activity
S: suicide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Indications for prescribing antidepressants

A

-Unipolar and bipolar depression(acute phase)
-organic mood disorders
-schizoaffective disorder
-anxiety disorders involving obsessive compulsive disorder
-Panic disorders
-Socia phobia
-PTSD
-PMDD
-impulsivity associated with personality disorders.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

General side effects of SSRI’s

A

-Central nervous system effects:
Headache, Dizziness, Tremors, Anxiety, Insomnia
-Hyponatremia: low sodium, mainly in older patients
-Sexual dysfunction: 50% of patients (decreased libido, erectile dysfunction, inability to achieve orgasm)
-Excessive sweating: 20% of patients.
-Gastrointestinal symptoms: Nausea, Diarrhea, Loose stools, weight loss or gain
-Anticholinergic effects: not as common as in Tricyclic Antidepressants
Dry mouth
Sedation
-Discontinuation Syndrome: agitation, nausea, disequilibrium and dysphoria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Fluoxetine General prescribing info:

A

FDA Approved: Major Depressive Disorder, Obsessive Compulsive Disorder, Panic Disorder, Social Anxiety Disorder, Treatment resistant major depressive disorder, Bipolar I disorder, acute depressive phase
Off label use: Cataplexy
Formulation: Tab and weekly cap
Dosing: 20-80mg daily
Long half-life (2-4 days)
Releases NE and DA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Fluoxetine clinical indications

A

Clinical Indications
Useful for depressed patients with reduced positive affect, apathy, fatigue
Decreased incidence of discontinuation syndromes
May be used in combination with olanzapine
Good for patients with medication noncompliance issues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Sertraline (Zoloft)

A

FDA Approved:
Major Depressive Disorder, Obsessive Compulsive Disorder, Panic Disorder, Premenstrual Dysphoric Disorder
Off label use: Bulimia
Formulation: Tab
Dosing: 50mg-200mg daily
Short half life
Dopamine transporter (DAT) inhibition
Less sedating than paroxetine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Sertraline Clinical Indications

A

Clinical Indications
Useful for depressed patients with low energy and mood reactivity
May be used with other antidepressants
Must take on full stomach
Increased number of GI adverse drug reactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Paroxetine:

A

FDA Approved:
Major Depressive Disorder, Panic Disorder, Obsessive Compulsive Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder, Post Traumatic Stress Disorder
Dosing: 20-50mg daily
Formulation: Tabs and continuous release (CR)
Short half life
Sedating properties (dose at night)
Limited norepinephrine (NET) inhibitory properties
Mild anticholinergic properties

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Paroxetine clinical indications

A

Clinical Considerations
Sedating, weight gain, more anticholinergic effects
Discontinuation syndrome is likely

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Fluvoxamine(Luvox)

A

FDA Approved:
Obsessive Compulsive Disorder
Off label use: Social Anxiety Disorder
Dosing: 50mg-100mg bid
Shortest ½ life
Binds to Alpha-1 receptors
Action is more potent than sertraline
GI distress, headaches, sedation, weakness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Fluvoxamine clinical indications

A

Useful for management of obsessive-compulsive disorder and anxiety disorder
May be used for psychotic and delusional depression
May have analgesic properties

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Citalopram

A

FDA Approved:
Major Depressive Disorder
Off label use: Obsessive Compulsive Disorder
Dosing: 20mg-40mg daily
Intermediate ½ life
Has mild antihistaminic properties, H1Antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Citalopram Clinical Indications

A

Clinical Indications
Well-tolerated
Useful for management of depression in elderly populations.
Dose-dependent QT interval prolongation with doses of 10-30mg daily. Doses of >40mg/day not recommended!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Escitalopram

A

FDA Approved:
Major Depressive Disorder
Off label use: Obsessive Compulsive Disorder
Dosing: 20mg-40mg daily
Intermediate 1/2 life
SERT inhibition
No antihistaminic properties
More effective than citalopram in acute response and remission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Escitalopram Clinical indications

A

Clinical Indications
Well-tolerated
Useful for patients with tendency to have QT prolongation
Dose-dependent QT interval prolongation with doses of 10-30mg daily
Nausea, headache

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Vilazodone(Viibryd)

A

FDA Approved: Major Depressive Disorder
Formulation: Tabs
Dosing: 20mg to 40mg po daily
-combined SSRI and 5HT1A receptor partial agonist
Metabolized in CYP-450 3A4, Use cautiously with 3A4 inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Vilazodone Clinical Indications

A

-May be helpful in treatment-resistant or treatment-refractory patients
-May increase bleeding in patients taking anticoagulants or medications that increase likelihood of bleeding
-GI disturbance most common side effect (nausea, diarrhea, constipation, abdominal pain)
-Other side effects: insomnia, sexual dysfunction, dry mouth, dizziness, rare hyponatremia/SIADH
Must take with food

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Vortioxetine(trintellix)

A

FDA Approved: Major Depressive Disorder
Formulation: Tabs
Dosing: 10mg po daily
-SSRI-Serotonin Receptor Modulator and stimulator (glutamate modulation)
-SERT inhibition (targets multiple serotonin receptors)
Metabolized in CYP-4502D6, Use cautiously with 2D6 inhibitors/inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Vortioxetine clinical indications

A

Clinical Indications
May be helpful in treatment-resistant or treatment-refractory patients
Improves the cognitive effects of depression
May increase bleeding in patients taking anticoagulants or medications that increase likelihood of bleeding
May cause seizures, mydriasis, sexual side effects and headache
GI disturbance most common side effect (nausea, diarrhea, constipation, abdominal pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Common SSRI drug interactions

A

-MAOI’s: Serotonin syndrome
-Lithium: increases lithium level
-Antipsychotic: increases EPS
-Benzodiazepines: increases half-life of benzodiazepines
-TCA: Increases TCA serum level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Overview of major SNRI’s

A

-Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
CYP 2D6, “Dual Action”, Combine SERT inhibition and the Norepinephrine transporter (NET) inhibition,
Increase serotonin, norepinephrine, and also dopamine in the prefrontal cortex
-Clinical Indications:
Used to treat depressive disorders and other conditions, Useful for patients with pain syndromes, Debatable if they achieve higher remission rates than SSRIs.
-General Side Effects: Nausea, dizziness, insomnia, excessive sweating, constipation, dry mouth, decreased appetite, headache, sexual side effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Venlafaxine

A

FDA Approved:
Major Depressive Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder
Off label use: Cataplexy, Migraine Headache, prophylaxis, PTSD
Formulation: cap and ER cap
Dosing: 75mg-225mg daily
Inhibits reuptake of both, serotonin (SRI) and norepinephrine transporter (NET)
SRI actions are seen with lower doses
NRI actions are seen with dose increases
-Available in extended-release and immediate-release forms
-Minimal drug interactions and almost no P450 activity
Short half-life and fast renal clearance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Venlafaxine Clinical Indications

A

Used for depression, and individuals with treatment-resistant depression
Approved and used for management of anxiety disorders
Can cause a 10-15 mmHG dose-dependent increase in diastolic BP.
May cause significant nausea, primarily with immediate-release (IR) tabs
Can cause a bad discontinuation syndrome, and taper recommended after 2 weeks of administration
Noted to cause QT prolongation
Sexual side effects in >30%

26
Q

Desvenlafaxine

A

FDA Approved: Major Depressive Disorder
Formulation: ER tab
Dosing: 50mg daily
Greater NET inhibition
Serotonin, Norepinephrine and Dopamine Reuptake Inhibitor
Minimal drug interactions
Short half-life and fast renal clearance avoids build-up

27
Q

Desvenlafaxine Clinical Indications

A

Clinical Indications
Used for depression
Useful to treat vasomotor symptoms, especially in women with depression and peri and post-menopausal
GI distress in 20%+
Dose related increase in total cholesterol, LDL and triglycerides
Dose related increase in BP

28
Q

Duloxetine

A

FDA Approved:
Major Depressive Disorder, Generalized Anxiety Disorder, Diabetic Peripheral Neuropathy, Fibromyalgia, Chronic Musculoskeletal Pain
Formulation: caps
Dosing: 60mg daily, max dose 120mg daily
Greater SERT inhibition, Lesser NET inhibition
Usually prescribed once a day, but it can be increased to twice a day as needed
Data to suggest efficacy for the physical symptoms of depression
Less BP increase as compared to venlafaxine
Clinical Indications
Cannot break capsule, as active ingredient not stable within the stomach

29
Q
A
30
Q

Norepinephrine Dopamine Reuptake Inhibitor(NDRI)

A

-The prototypical agent is bupropion
-Mechanism of action remains unclear
-A main hypothesis points out that it inhibits the reuptake of dopamine (dopamine transporter or DAT inhibitor)
-Inhibits reuptake of norepinephrine (norepinephrine transport or NET inhibitor)
-Considered an active drug and a precursor for other active drugs

31
Q

Bupropion (Wellbutrin/Zyban)

A

-Activating, decreased appetite
-Can be problematic for patients with anxiousness/irritability
-Can produce false-positive urine test results for amphetamines
-No sexual side effects (can reverse sexual side effects of other antidepressants)
-Improves concentration
-Side effects: Agitation, insomnia, headache, nausea, vomiting, tremor, jerks, tachycardia, dry mouth, weight loss.
-Rare risk: Seizures (higher dosages, rapid dose increase), avoid in patients with binge/purge behavior

32
Q

SARI(Serotonin Antagonist and reuptake inhibitor

A

Clinical Indications
Useful for treatment of depression
Used to manage insomnia in patients with major depression
It can augment the efficacy of other antidepressants
Block serotonin 2A (5HT 2A) and 2C (5HT 2C) receptors
Also increases reuptake of serotonin

33
Q

Serotonin Modulators

A

5HT2 inhibitors
Both antagonist and agonist of serotonin
Less effect on norepinephrine
Affects multiple serotonin receptors
Less sexual dysfunction, anxiety or insomnia
Side effects: orthostatic hypotension, drowsiness, dry mouth, blurred vision, nausea, vomiting
Examples: Mirtazapine (Remeron), Trazodone (Desyrel)
Nefazodone (Serzone), Vilazodone (Viibryd),
Vortioxetine (Trintellix)

34
Q

Trazodone

A

FDA Approved: Major Depressive Disorder
Off label Use: Insomnia
Formulation: immediate release and controlled released
Dosing: 50mg-100mg MDD, 25-50mg Insomnia

Short half-life
Antagonist of 5HT2A and 5HT2C
Has both antidepressant and sedative effect
Less sexual disfunction, anxiety or insomnia
Side effects: orthostatic hypotension, priapism, drowsiness, dry mouth, blurred vision, nausea, vomiting

35
Q

Nefazodone(Serzone)

A

FDA Approved: Major Depressive Disorder
Off label use: Premenstrual Syndrome
Dosing: 150mg-300mg tabs
Lower SERT inhibition, also NET inhibition

Side effects: orthostatic hypotension, less risk of priapism, drowsiness, dry mouth, blurred vision, nausea, vomiting

36
Q

Tricyclic Antidepressants (overview)

A

Block reuptake of norepinephrine transporter
Some TCAs have greater serotonin inhibition, others more selected norepinephrine inhibition
High protein binding, high lipid solubility
Many side effects have been identified (anticholinergic, antihistaminic, antiadrenergic)
Cause increased sedation
Cause increased anticholinergic actions
Can cause postural hypotension and dizziness
Can be lethal in an overdose (QT prolongation)
Amitriptyline (Elavil)
Clomipramine (Anafranil)
Imipramine (Tofranil)
Doxepin (Sinequan)
Nortriptyline (Pamelor)

37
Q

Amitriptyline (Elavil)

A

Tricyclic:
FDA Approved: Major Depressive Disorder
Off label use: neuropathic pain, fibromyalgia, migraine headache, post-herpetic neuralgia
Dosing: 50mg-150mg qhs
Potent sedative

Side effects: Increased weight gain, black tongue unpleasant taste, anticholinergic effects, weight gain (particularly at doses below 45mg), decrease sex drive, decrease urination, erectile dysfunction, cardiac changes.
-Beers Criteria: avoid in elderly

38
Q

Clomipramine (anafranil)

A

Tricyclic
FDA Approved: Obsessive Compulsive Disorder
Off label use: cataplexy, confusional arousals, sleep terrors, sleep walking
Dosing: 150mg-250mg qhs caps
Closely related to antipsychotic drugs (phenothiazines)
Side effects: dry mouth, constipation, blurred vision, mydriasis, metallic taste, urinary retention, sedation, weight gain, no sexual side effects;

39
Q

Nortriptyline(Pamelor)

A

Tricyclic
FDA Approved: Major Depressive Disorder
Dosing: 50mg-150mg qhs
Metabolite of amitriptyline

40
Q

Doxepin (Sinequan)

A

Tricyclic
FDA Approved: depression, anxiety
Off label use: insomnia, alcohol dependence, chronic urticaria
Dosing: 150mg-300mg qhs

41
Q

Imipramine(Tofranil)

A

Tricyclic:
FDA Approved: Major Depressive Disorder (MDD)
Off label use: treatment resistant generalized anxiety disorder, chronic pain, confusional arousals, sleep terrors, sleep walking, nocturnal enuresis (older than 6 years)
Dosing: 150mg-300mg qhs MDD
Closely related to antipsychotic drugs (phenothiazines)
Side effects: dry mouth, constipation, blurred vision,
mydriasis, metallic taste, urinary retention, sedation, weight gain, no sexual side effects; rare agranulocytosis/neutropenia

42
Q

Mirtazepine (remeron)

A

Tetracyclic Antidepressant
FDA Approved: Major Depressive Disorder
Formulation: tabs and oral disintegrating tablet (ODT)
Dosing: 15mg-45mg MDD
Can be utilized as a hypnotic at lower doses
May be a good medication to augment with antidepressant
Cons
Increases serum cholesterol and triglycerides
Very sedating at lower doses, activating at doses 30mg and above
Associated with weight gain (particularly at doses below 45mg
Side effects: Somnolence, increased appetite, weight gain, no sexual side effects; rare agranulocytosis/neutropenia

43
Q

Serotonin Syndrome may occur if SSRI is combined with:

A

Tryptophan
SNRIs
MAOIs
TCAs
Bupropion
Amphetamines, Lysergic acid diethylamide (LSD), ecstasy, cocaine
Opioids, opiates, dextromethorphan
St. John’s Wort, ginseng, nutmeg
Tegretol, lithium, valproic acid

44
Q

Serotonin Syndrome mneumonic

A

ARMS: A: anxiety, R: restlessness, M: myoclonus, S: sweating

45
Q

Serotonin Syndrome Symptoms

A

Symptoms can be from mild to severe
Cognitive effects: confusion, hypomania, hallucinations, agitation, coma.
Autonomic effects: shivering, sweating, hyperthermia, hypertension, tachycardia, nausea, diarrhea.
Somatic effects: ataxia, myoclonus, twitching, hyperreflexia, rigidity, tremor.
Treatment:
Stop SSRI, stabilize temperature, benzodiazepine for muscle relaxation, beta-blocker for tachycardia.

46
Q

MAOI Clinical Indications

A

Clinical Indications
Used to manage depression, primarily due to inhibition of MAO-A
Antidepressant efficacy is also believed to be achieved due to concurrent inhibition of both MAO-A and MAO-B
MAOIs are also used to manage Parkinson’s Disease

47
Q

MAOI clinical indications

A

Action: Inhibit enzyme responsible for the metabolism of serotonin, dopamine, norepinephrine, and tyramine.
Increases levels of norepinephrine and serotonin in the CNS
Interacts with food – low tyramine diet
Non-selective Monoamine Oxidase Inhibitors
Particularly effective for ”atypical depression”: overeating, oversleeping, rejection sensitivity, mood reactivity

48
Q

MAOI prescribing guidelines/considerations

A

Switching with serotonergic agents
A complete washout of a serotonergic agent is required
For most serotonergic agents is 5 to 7 days
For fluoxetine, the washout period should be 5 weeks
If switching an MAOI to a SSRI, 14 days must be allowed to start an MAOI.

49
Q

Dietary Restrictions with MAOI’s.

A

Dietary Restriction: Avoid high tyramine, tryptophan, phenylalanine, or tyrosine (aged cheese, cured meats, fava or broad bean pods, tap/draft beers, marmite, sauerkraut, soy sauce, over-ripe fruit, spoiled foods) to avoid a Hypertensive Crisis.

50
Q

Additional MAOI prescribing Considerations:

A

-Hypertensive Crisis: Systolic blood pressure > 120 mmHg, occipital headache, palpitations, neck stiffness, nausea, vomiting, sweating, dilated pupils, tachycardia or bradycardia, may be associated with chest pain
-Medication Avoidance: Other antidepressants, stimulants, sympathomimetics, dextromethorphan, meperidine, disulfiram
-Main Side effects: dizziness, headache, orthostatic hypotension, dry mouth, constipation, drowsiness (Nardil), tremor, sweating, peripheral edema, sexual side effects, weight gain (Nardil)
-Do not use within 5 weeks of Fluoxetine and 2 weeks of other antidepressants;
-Washout period= Wait 2 weeks after stopping MAOI to start other antidepressant

51
Q

Manic Switch

A

Sometimes referred to as a psychiatric event
Especially concerning when there is a family history of bipolar disorder
Screen patients for hypomania or mania prior to prescribing
If signs of mania or worsening of a pre-existing illness occur, dose reduction or discontinuation may be considered

52
Q

Discontinuation Syndrome

A
53
Q

Tyramine Rich foods

A

Beverages
Beverages with caffeine
Red wine and sherry
Homemade beer
Foods
All strong or mature cheese
Smoked/processed meats
Sour cream
Yogurt
Avocado
Soy Sauce
Chocolate

54
Q

No Response (R’s of depression)

A

Improvement of <25%

55
Q

Partial Response

A

Partial Response: Improvement of 25-49%

56
Q

Response

A

Response: Improvement of >=50%

57
Q

Remission

A

Remission: Complete resolution of symptoms

58
Q

Relapse

A

Relapse: Return of depression symptoms within 6 months of remission

59
Q

Recovery

A

Recovery: Absence of symptoms for at least 6 months following remission

60
Q

Recurrence

A

Recurrence: New episode after recovery

61
Q

Resistant

A

Resistant: Failure of two or more trials

62
Q

Refractory

A

Refractory: Highly resistant to treatment and do not respond

PMHNP (15 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions